KENILWORTH, N.J., May 27 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP) today announced that Janet M. Barth has been appointed vice president, investor relations, effective immediately.
In this role, Barth will be responsible for developing, implementing and continually improving a comprehensive global investor relations program for Schering-Plough. She will lead the formulation and execution of external and internal investor communications plans to support Schering-Plough's business objectives. She also will partner with the company's senior management team on matters pertaining to the investment community and individual shareholders.
Barth reports to Alex Kelly, group vice president, global communications and investor relations. She assumes the investor relations responsibilities that were previously fulfilled by Kelly, who was named to his current expanded role in October 2007.
Barth most recently served as senior vice president, investor relations and corporate communications, for Adams Respiratory Therapeutics, which was a newly public specialty pharmaceutical company. In that role, she established, developed and directed comprehensive investor relations and corporate communications programs for the company prior to its acquisition by Reckitt Benckiser in January 2008.
Previously, Barth was employed for 14 years by Schering-Plough, where she held various positions of increasing responsibility, including that of director, investor relations. Barth holds a Bachelor of Arts degree in policy and management studies from Dickinson College, Carlisle, Pa., and a Master of Business Administration degree from Seton Hall University, South Orange, N.J. She joined the National Investor Relations Institute (NIRI) in 1996 and currently is a member of NIRI's New York and Virtual Chapters. Barth completed a 12-month leadership development program with Women Unlimited LEAD (Leadership Education and Development) in 2005.
Schering-Plough is an innovation-driven, science-centered global health care company. Through its own biopharmaceutical research and collaborations with partners, Schering-Plough creates therapies that help save and improve lives around the world. The company applies its research-and-development platform to human prescription and consumer products as well as to animal health products. Schering-Plough's vision is to "Earn Trust, Every Day" with the doctors, patients, customers and other stakeholders served by its colleagues around the world. The company is based in Kenilworth, N.J., and its Web site is http://www.schering-plough.com.
|SOURCE Schering-Plough Corporation|
Copyright©2008 PR Newswire.
All rights reserved